NYSE:BSX - Boston Scientific Stock Price, Price Target & More

Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

Boston Scientific Co. (NYSE:BSX) announced its quarterly earnings results on Wednesday, April, 25th. The medical equipment provider reported $0.33 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.32 by $0.01. The medical equipment provider had revenue of $2.38 billion for the quarter, compared to analyst estimates of $2.34 billion. Boston Scientific had a net margin of 1.21% and a return on equity of 25.10%. Boston Scientific's revenue for the quarter was up 10.1% compared to the same quarter last year. During the same period last year, the business earned $0.29 EPS. View Boston Scientific's Earnings History.

Boston Scientific is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for Boston Scientific.

Boston Scientific issued an update on its FY18 earnings guidance on Wednesday, April, 25th. The company provided earnings per share guidance of $1.37-1.41 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.37. The company issued revenue guidance of $9.75-9.90 billion (+5-7% organic), compared to the consensus revenue estimate of $9.75 billion.Boston Scientific also updated its Q2 guidance to $0.33-0.35 EPS.

21 Wall Street analysts have issued 12 month target prices for Boston Scientific's shares. Their predictions range from $27.00 to $36.00. On average, they anticipate Boston Scientific's stock price to reach $32.3810 in the next twelve months. View Analyst Ratings for Boston Scientific.

Some companies that are related to Boston Scientific include 3M (MMM), Stryker (SYK), Becton Dickinson and (BDX), FRESENIUS SE &/S (FSNUY), Baxter International (BAX), ABIOMED (ABMD), ResMed (RMD), Teleflex (TFX), Dexcom (DXCM), ICU Medical (ICUI), Hill-Rom (HRC), Insulet (PODD), Globus Medical (GMED), Penumbra (PEN) and Haemonetics (HAE).

Media coverage about BSX stock has trended somewhat negative this week, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Boston Scientific earned a media sentiment score of -0.02 on Accern's scale. They also gave news stories about the medical equipment provider an impact score of 44.30 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Boston Scientific's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.70%), Bollard Group LLC (2.44%), Artisan Partners Limited Partnership (1.94%), Northern Trust Corp (1.08%), Wells Fargo & Company MN (0.93%) and Newport Trust Co (0.78%). Company insiders that own Boston Scientific stock include Arthur C Butcher, Daniel J Brennan, David A Pierce, Eric Francis Yves Thepaut, Jeffrey B Mirviss, John Bradley Sorenson, Joseph Michael Fitzgerald, Keith D Dawkins, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Michael P Phalen, Supratim Bose, Timothy A Pratt, Valley Gold Master Fund L Sun and Wendy Carruthers. View Institutional Ownership Trends for Boston Scientific.

BSX stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., Boston Partners, Artisan Partners Limited Partnership, Prudential Financial Inc., State of Tennessee Treasury Department, Natixis, Russell Investments Group Ltd. and Swiss National Bank. Company insiders that have sold Boston Scientific company stock in the last year include Arthur C Butcher, Daniel J Brennan, David A Pierce, Eric Francis Yves Thepaut, Jeffrey B Mirviss, John Bradley Sorenson, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Michael P Phalen, Supratim Bose, Timothy A Pratt and Wendy Carruthers. View Insider Buying and Selling for Boston Scientific.

BSX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Eaton Vance Management, Cannell Peter B & Co. Inc., Bodenholm Capital AB, Point72 Asset Management L.P., Wells Fargo & Company MN, Anchor Capital Advisors LLC and Royal Bank of Canada. View Insider Buying and Selling for Boston Scientific.

Shares of BSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of BSX stock can currently be purchased for approximately $32.62.

Boston Scientific has a market capitalization of $44.36 billion and generates $9.05 billion in revenue each year. The medical equipment provider earns $105 million in net income (profit) each year or $1.26 on an earnings per share basis. Boston Scientific employs 29,000 workers across the globe.

Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected]